SCHEDULE: Soleus Capital Discloses 5.2% Stake in Geron Corp.

Soleus Capital Master Fund and its affiliates have reported a 5.2% beneficial ownership stake in Geron Corporation, totaling 33,008,659 shares.

Summary

• Soleus Capital Master Fund, L.P., along with its affiliated entities (Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC) and Guy Levy, collectively reported beneficial ownership of 33,008,659 shares of Geron Corporation's common stock.
• This ownership represents 5.2% of Geron Corporation's outstanding common stock.
• The percentage is calculated based on 640,544,661 shares outstanding as of February 20, 2026, as reported in Geron's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
• All reporting persons share both voting and dispositive power over the 33,008,659 shares.
• The shares were not acquired for the purpose of changing or influencing control of Geron Corporation.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it signals institutional confidence in Geron Corporation without indicating any immediate operational changes or challenges. It's a standard disclosure with a positive underlying implication of investor interest.

Positives

• A significant institutional investor, Soleus Capital, has taken a substantial stake in Geron Corporation, potentially signaling confidence in the company's future prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Geron Corporation's future performance or Soleus Capital's investment strategy beyond the beneficial ownership disclosure.

Management Comments

• The filing includes a certification from Guy Levy, on behalf of all reporting persons, stating that the securities were not acquired and are not held for the purpose of changing or influencing the control of Geron Corporation.

Industry Context

StockSavvy.ai notes that a 5.2% stake by an institutional investor like Soleus Capital in a biotechnology company such as Geron Corporation can be viewed positively, as it indicates a significant commitment and potential belief in the company's long-term value proposition, particularly in a sector often characterized by high R&D costs and regulatory hurdles. This level of ownership often suggests a strategic, long-term investment rather than short-term trading.

Comparison to Industry Standards

• A 5.2% stake is a notable position for an institutional investor, often placing them among the top shareholders. For instance, similar stakes by funds like BlackRock or Vanguard in other biotech firms (e.g., Moderna, BioNTech) are common and are generally seen as a vote of confidence.
• Compared to activist investors who might take a similar stake to push for corporate changes, Soleus Capital's explicit disclaimer of intent to influence control suggests a more passive, long-term investment approach, aligning with typical institutional fund strategies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may instill confidence among existing shareholders and attract new investors, potentially supporting the stock price.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for Geron Corporation or Soleus Capital's investment strategy.

Key Dates

Recommendation

The disclosure of a 5.2% beneficial ownership by Soleus Capital is a positive signal of institutional confidence in Geron Corporation. However, as a Schedule 13G, it is a passive filing and does not provide new operational or financial data to warrant a 'buy' recommendation. It primarily confirms a significant investor's position, suggesting a 'hold' for existing investors and a 'neutral' stance for potential new investors until further operational updates from Geron Corporation are available.

Keywords

Geron Corporation, Soleus Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Equity Stake, Biotechnology, Pharmaceuticals